Bioasis Names Antalik as Chief Financial Officer
11 January 2019 - - US-based research-stage biopharmaceutical company Bioasis Technologies Inc. (TSX.V: BTI) (OTCQB: BIOAF) has appointed Christine Antalik as chief financial officer, the company said.

Antalik has previously worked at a number of life sciences companies and brings diverse financial management experience in executing the strategic and financial plans of emerging companies with consistent successes in improving the performance and value of companies.

Christine Antalik has more than 25 years of experience in accounting and finance including several high-profile, executive-level roles as chief financial officer.

Over the course of her career, Antalik has closed over USD 800m in deal transactions through initial public offerings, private and venture equity financings, debt financings, recapitalisations, research grants and mergers and acquisitions.

With four consecutive exits over eleven years, she has an impeccable track record of starting, building, growing and improving the profitability, performance and value of companies, while positioning them for the next level of growth or exit.

Antalik is the managing member of Founders Bridge Advisors, LLC, a business advisory firm located in Connecticut, and has served as chief financial officer of Aeromics, Inc. since October 2016.

Previously, Antalik served as chief financial officer of SurgiQuest, Inc. where she led the USD 265m acquisition of SurgiQuest, Inc. by Conmed Corp. after filing the company's public S-1 statement.

Antalik closed a USD 108m initial public offering as the vice president of finance and controller at HigherOne, Inc., a financial technology company.

Prior to HigherOne, Antalik served as controller for Tangoe, Inc., a software service company.

As chief financial officer and treasurer of Hematech, LLC, Antalik formed a joint venture with a key services provider to mitigate business risk and ultimately steered the company to a successful exit, being acquired by Kirin Brewery company, Ltd.

Antalik also previously served as controller and senior manager of litigation support and business valuation for Centerprise Advisors, Inc. (currently Marcum, LLP), a national consulting and accounting advisory firm, where she provided expert witness reports in economic damages cases, business valuations and forensic accounting services.

Antalik earned her bachelor of science degree in business administration from Western New England College, Springfield, Mass.

As a result of her appointment, the company has granted Antalik stock options to acquire a total of 95,000 common shares.

These options vest over a period of 12 months from the date of the grant, expire five years from the date of the grant and are governed by the terms of the company's stock option plan.

The exercise price of these options will equal the closing price of the company's common shares on the TSX Venture Exchange immediately following the expiry of the current "blackout" period under the company's insider trading policy as a result of the filing of Bioasis audited financial statements and MD and A for its fiscal year ended Sept. 30, 2018.

Bioasis Technologies is a biopharmaceutical company developing the xB3 TM platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.

The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders.

The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis maintains headquarters in Guilford, Conn., United States.